## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.87 indicates fundamental undervaluation. Quality metrics strong (ROE 31%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($63.27)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 1, Bearish: 8)

**1. DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm**
- Source: GlobeNewswire | 20251223T003222 | Bearish | Relevance: 100%
- Bragar Eagel & Squire, P.C. announced a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) for allegedly making false and misleading statements regarding the safety and efficacy of its G6 and G7 devices. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, are encouraged to contact the firm before the December 26, 2025 deadline to apply for lead plaintiff. The lawsuit claims DexCom made unauthorized design changes that rendered the devices less reliable, posing a health risk to users.

**2. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (NASDAQ: DXCM)**
- Source: GlobeNewswire | 20251222T141741 | Bearish | Relevance: 100%
- Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against DexCom, Inc. on behalf of investors who purchased shares between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made misrepresentations regarding the accuracy and functionality of its G7 continuous glucose monitoring system. Shareholders who invested in DexCom during this period and wish to serve as lead plaintiff must file papers by December 26, 2025.

**3. Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential**
- Source: Insider Monkey | 20251222T140010 | Bullish | Relevance: 100%
- Morgan Stanley upgraded DexCom (DXCM) to Overweight with a $75 price target, citing an undervalued recovery and G7 rollout margin potential. This upgrade comes despite Evercore ISI initiating coverage with an In Line rating due to anticipated headwinds like product quality concerns and competitive threats. Separately, DexCom announced FDA clearance for Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for Type 2 diabetes patients.

**4. Important December 26, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Investors of Securities Fraud Class Action Lawsuit**
- Source: The Malaysian Reserve | 20251220T170759 | Bearish | Relevance: 100%
- Kessler Topaz Meltzer & Check, LLP is reminding DexCom, Inc. investors about a securities fraud class action lawsuit with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made materially false and/or misleading statements regarding design changes to its G6 and G7 continuous glucose monitoring systems, which were unauthorized by the FDA and posed health risks. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to contact the law firm.

**5. Dexcom Names Jacob Leach as Incoming Chief Executive**
- Source: TipRanks | 20251222T220723 | Somewhat-Bullish | Relevance: 100%
- Dexcom has announced that Jacob S. Leach will become President, Chief Executive Officer, and director on January 1, 2026, following Kevin R. Sayer's resignation. Leach's compensation package includes a significant salary, bonus, and stock units, while Sayer is expected to return as board chairman in March 2026. Spark's AI Analyst rates DXCM as "Outperform" due to strong financial performance and positive earnings sentiment.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Mizuho | $78 | $75 | +4% |
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Mizuho | main | Outperform |
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)
- JPMORGAN CHASE & CO: 3.2% (+101.9%)

### Key Risks

1. Long-term trend broken: trading 8.9% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (3 raises, avg +9%). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.4B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 27.2 |
| Current P/E | 32.7 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.9% to 2.7% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.3pp (needs >4.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. AM_20 at 3.2% shows strong absolute momentum above own 20MA. Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 60. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.66% (CS: 71) | Neutral |
| RSI_14 | 60.0 | Neutral |
| MACD Histogram | 0.14 | Bullish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.053x | Above |
| vs SMA200 | 0.911x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $67.43
- **Stop Loss:** $63.27 (6.2% risk)
- **Target:** $75.75 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 288
- **Position Value:** $19,419.84
- **Portfolio %:** 19.42%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*